Finance analyst: Novo's sales from obesity drugs may grow earlier than anticipated
Novo Nordisk may see accelerated sales of obesity drugs sooner than expected, thinks Danish bank analyst, who sees great potential in upcoming new data for semaglutide as an obesity treatment.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Preliminary data from a crucial trial concerning a Novo Nordisk obesity drug may accelerate sales in 2023, according to Danish newspaper Børsen in reference to an analysis from Danish bank and financial analyst Nordea.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk appoints new head of drug discovery
For subscribers
Novo Nordisk Pharmatech lands record profits in 2020
For subscribers
